

Announcement of Agreements with Shionogi & Co., Ltd. for Research Collaboration and Grant of First Refusal Right

Sapporo and Osaka, Japan, July 15, 2016 - NB Health Laboratory Co. Ltd. (Head Office: Kita Ward, Sapporo; President: Kiyoshi Takayama, Ph.D.; “NBHL”) and Shionogi & Co., Ltd. (Head Office: Chuo Ward, Osaka; President and CEO: Isao Teshirogi, Ph.D.; “Shionogi”) today announced that NBHL and Shionogi have established an agreement for collaborative research with the aim of exploring novel drug candidates for infectious diseases, as well as an agreement for right of first refusal granted to Shionogi regarding outcomes of the research in the field of infectious diseases, which NBHL has been conducting in collaboration with Hokkaido University.

Following these agreements, NBHL will set up a new laboratory in “Shionogi Innovation Center for Drug Discovery” owned by Shionogi on the campus of Hokkaido University. NBHL’s ten years of experience of biochemical and functional assay development will promote collaborative research with Shionogi, in order to pursue the discovery of small compounds for infectious diseases. Ongoing research collaboration for generating therapeutic antibodies in the field of infectious diseases between NBHL and Specially Invited Professor Hiroshi Kida, Research Center for Zoonosis Control, Hokkaido University, will also be accelerated in this center, and first refusal right regarding the outcomes of the research will be given to Shionogi.

“Shionogi Innovation Center for Drug Discovery” served as the pivot of “The Matching Program for Innovations in Future Drug Discovery and Medical Care” (from July, 2006 to March, 2016) of Shionogi and Hokkaido University, and numerous results have been yielded in this center. NBHL will participate together with Shionogi in “Center for Life Innovation” (Director: Professor Katsumi Maenaka) founded this year at Hokkaido University, will strive for drug discovery in the field of infectious diseases by utilizing “Shionogi Innovation Center for Drug Discovery”, and will promote R&D in an open innovation style by industry-academia collaboration with Hokkaido University.

About Shionogi & Co., Ltd. (“Shionogi”)

Shionogi & Co., Ltd. has been researching, developing and distributing innovative infectious disease drugs for more than fifty years. Shionogi is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. In addition to in-house-research activity, Shionogi is focusing on utilization of outer resources from collaborative research with partners such as academia and other companies in order to contribute to patients.

For further information, contact:

Corporate Communications Department

Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596

About NB Health Laboratory Co. Ltd. (“NBHL”)

NBHL is a biotechnology company with a core technology for antibody production, MoGRAA™ discovery engine, dedicated to generating new drug candidates for respiratory diseases, infectious diseases, chronic inflammation and central nervous system disorders, while NBHL also provides state-of-the-art drug discovery platform.

By continuously striving to improve its drug discovery competence and technology for creation of “new concepts of medicines”, and with an awareness of the views of patients and clinicians, NBHL accelerates its R&D to deliver medicines truly desired to the clinical practice.

Founded in July, 2006

Head Office Address: Sapporo, Hokkaido, Japan

Founder and President: Kiyoshi Takayama, Ph.D.

Contact personnel: Tomoko Shimizu, Director of BD

TEL: +81-11-708-7156

URL: <http://www.nbhl.co.jp/>